INTERNATIONAL CONGRESS ON HEMATOLOGIC Malignancies®

Use code HEM19NEWS1 to save!

The American Journal of Hematology/Oncology® update

A Message From A Chair

Andre H. Goy, MD, MS

In the time since we last gathered for the **International Congress on Hematologic Malignancies®**, we've seen dozens of new or expanded approvals in hematology. The strides we have made in 2018 and the exciting developments and expectations for 2019 make me proud to be a hematologist oncologist and equally excited to invite you to participate in this year's conference.

Beyond the expanding data on game changing CAR T-cell therapy, every field this year has seen profound changes: acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), peripheral T-cell lymphoma (PTCL), but also Waldenström macroglobulinemia and hairy cell leukemia!

Together with the leading experts we will discuss and review how these changes impact the way we manage our patients' care.

Sincerely,

Andre H. Goy, MD, MS
Chairman and Executive Director Lymphoma
Division Chief- John Theurer Cancer Center
Hackensack, NJ

JOIN US FOR THIS YEAR'S MEETING!

Thursday, February 28 – Sunday, March 3, 2019

EDEN ROC MIAMI BEACH
4525 COLLINS AVENUE
MIAMI BEACH, FL, 33140

Benefits of Attending This Meeting:

- Understand how and when to use CAR T-cells and their future impact
- Review and discuss data on novel agents across the board in hematologic malignancies
- Learn how and when to use biomarkers and MRD in treating patients with lymphoma, leukemia, or myeloma
- Explore new solutions and upcoming changes in healthcare delivery including new reimbursement models and value-based care
- Personal interaction with peers and experts including discussing your challenging cases with an international panel of experts.

Register with code HEM19NEWS1 to save 25%

For more information and to register, visit, gotoper.com/go/HEM19NEWS1

PER® Physicians' Education Resource, LLC

SOME OF 2018'S BIGGEST HEADLINES

FDA drug approvals in hematologic malignancies throughout 2018 have changed the treatment paradigm of multiple diseases and resulted in necessary updates to treatment guidelines and best practices. Here we preview some of the recent approvals and practice-changing data that will be covered at this year's **International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma**.

Waldenström Macroglobulinemia

It's not every year that we we cover or even make ground in Waldenström macroglobulinemia. But this rare form of B-cell lymphoma, characterized by lymphoplasmacytic cells infiltrating the bone marrow, saw the FDA approval of ibrutinib plus rituximab in 2018, expanding the indication for ibrutinib in this disease.

This approval was based on new data from the phase III iNNOVATE trial, in which 150 patients with untreated or relapsed/refractory disease were randomized to receive either ibrutinib or placebo, in combination with rituximab. The 30-month progression-free survival (PFS) was significantly higher for the patients in the ibrutinib arm compared with placebo: 82% vs 28%, respectively. Patients receiving the combination had an 80% lower risk of disease progression or death.

Hairy Cell Leukemia

Hairy cell leukemia (HCL), a rare B-cell leukemia, also saw new advances this year with the approval of the CD22-directed cytotoxin moxetumomab pasudotox. The antibody portion of the compound directs the agent to CD22-expressing leukemic cells, where upon entry, the toxin inhibits protein synthesis, inducing apoptosis.

This approval came from the phase III study evaluating the efficacy of moxetumomab pasudotox in 80 patients with relapsed or refractory HCL, in which the objective response rate (ORR) at 16.7 months was 75%. Futher, 33 patients (41%) had achieved a complete response.

Chronic Leukemias

2018 was also a busy year for chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). In September, the FDA approved duvelisib for use in patients with relapsed or refractory CLL (as well as follicular lymphoma and small lymphocytic lymphoma [SLL]) based on the results of the phase II DYNAMO trial and the phase III DUO.

DYNAMO evaluated 129 patients with non-Hodgkin lymphoma, including 83 with follicular lymphoma. The ORR in patients with follicular lymphoma was 41%, and the median overall survival (OS) was 18.4 months. In DUO, duvelisib was compared with ofatumumab in patients with relapsed or refractory CLL/SLL. In these patients, duvelisib significantly improved median PFS to 13.3 months with duvelisib compared with 9.9 months on ofatumumab. The ORR for patients receiving duvelisib was 74%, compared with 45% in patients who received ofatumumab.

Earlier in June, the FDA granted the regular approval of venetoclax for patients CLL or SLL with or without 17p deletion who have received at least one prior therapy. This approval was based on the phase III MURANO trial, in which 389 patients were randomized to receive venetoclax or bendamustine, both in combination rituximab. After a median follow-up of 23 months, the median PFS had not been reached in the venetoclax arm compared with 18.1 months in patients receiving bendamustine. The ORR was 92% and 72% for venetoclax and bendamustine, respectively.

Chronic Leukemias Continued



For CML, new approvals came in March of 2018 when the FDA approved the use of nilotinib for the first- and second-line treatment of pediatric patients aged 1 year and older with Philadelphia chromosome–positive CML in the chronic phase. This approval was based on a cohort of 69 pediatric patients with Ph+ CML-CP enrolled across 2 trials. Patients were either newly diagnosed or resistant/intolerant to prior treatment with a tyrosine kinase inhibitor.

The major molecular response (MMR) in newly diagnosed patients was 60% at 12 cycles, and the median time to first MMR was 5.6 months. In the resistant/intolerant group, the MMR rate was 40.9% at 12 cycles, and the median time to first MMR was 2.8 months.

This combined with the approvals of dasatinib and bosutinib in late 2017 have transformed the way we treat this disease and will be discussed at the Winter Hematology® meeting.

This Year's Agenda "Highlights"

Thursday, February 28

CAR T Preconference Workshop: Leukemias, Lymphomas, Myelomas, and Solid Tumors
Joseph A. Fraietta, PhD; Andre H. Goy, MD, MS; Frederick L. Locke, MD; Denis Migliorini, MD; Jae H. Park, MD; Noopur Raje, MD; and Loretta J. Nastoupil, MD

Friday, March 1

What to Do for Patients with Diffuse Large B-Cell Lymphoma When R-CHOP Alone Is Not Enough
Andre H. Goy, MD, MS

What Is the Goal for Patients with Mantle Cell Lymphoma: Long Remission or Cure?
Simon Rule, MD

Beyond Genomics: Integrating Molecular Medicine in Our Practice
Maher Albitar, MD

Picking Frontline Therapy for Follicular Lymphoma in 2019
Jia Ruan, MD, PhD

The Potential of Gene Therapy in Benign Hematology
Punam Malik, MD

Staging, Risk Assessment, and Induction Therapy Selection for Patients with Multiple Myeloma
Thomas G. Martin, MD

Tailoring Approaches for Patients with PH-Like/PH- Positive Acute Lymphoblastic Leukemia
Elias Jabbour, MD

Plenary Lecture: Cells as Pills: Stem Cells for Regenerative Medicine Applications (can we make this a different color because its plenary?)
Eckhard U. Alt, MD PhD

Monoclonal Antibodies in Acute Lymphoblastic Leukemia
Naval G. Daver, MD

Development of MRD Assessment in Hematologic Malignancies
Naval G. Daver, MD

Saturday, March 2

Choosing Frontline Therapy in Chronic Lymphocytic Leukemia: No More Chemotherapy?
Matthew S. Davids, MD, MMSc

Emerging New Agents in Chronic Lymphocytic Leukemia
Jacqueline C. Barrientos, MD, MS

KEYNOTE: Avoiding Physician Burnout
Tait Shanafelt, MD

Value-Based Medicine Session
Andre H. Goy, MD, MS; Allen J. Karp; and Andrew Norden, MD, MPH, MBA

Managing Older Patients with Acute Myeloid Leukemia: How Has Therapy Changed?
Richard M. Stone, MD

How Does Precision Medicine Fit in the Value-Based Care Environment to Reduce Variance in Outcomes?
Andrew Norden , MD, MPH, MBA

What's New for Patients with Waldenström's Macroglobulinemia?
Morie A. Gertz, MD, MACP

Sunday, March 3

New Treatment Approaches for Patients with Myelodysplastic Syndromes
David P. Steensma, MD

Agonists and Inhibitors: New Tools for Immune Thrombocytopenia Treatment Discontinuation in Chronic Myeloid Leukemia: Who and When?
Jorge Cortes, MD

Treating Myelofibrosis with JAK Inhibitors: Has Anything Changed?
Katherine Walsh, MD

Tailoring Treatment for Patients with Hodgkin Lymphoma
Craig H. Moskowitz, MD

Emerging Agents for Late Relapse in Multiple Myeloma
Sagar Lonial, MD, FACP

Plenary Lecture (scientific): Precision Payment Impact of Real-World Data to Optimize the Sequence of Care in Multiple Myeloma
Daniel Auclair, PhD

INTERNATIONAL CONGRESS ON
HEMATOLOGIC
Malignancies® update

2 Clarke Drive, Suite 110
Cranbury, NJ 08512

Phone: (609) 378-3701
E-mail: info@gotoper.com

> **"This meeting helps us to stay current in a field that is so broad and ever changing"**
>
> – 2018 Attendee

23rd Annual INTERNATIONAL CONGRESS ON HEMATOLOGIC Malignancies®

FOCUS ON LEUKEMIAS, LYMPHOMAS, AND MYELOMA

Winter HEMATOLOGY®

Use code HEM19NEWS1 to save!

Thursday, February 28 – Sunday, March 3, 2019

NEW VENUE • EDEN ROC • MIAMI BEACH
4525 Collins Ave, Miami Beach, FL 33140

Co-Chairs

Andre H. Goy, MD, MS

Chairman and Executive Director
Lymphoma Division Chief - John Theurer Cancer Center
Chief Science Officer – RCCA
Lydia Pfund Chair for Lymphoma
Professor of Medicine, Georgetown University
Hackensack, NJ

Sagar Lonial, MD, FACP

Professor, Emory School of Medicine
Chair, Department of Hematology & Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA

Jorge Cortes, MD

Jane and John Justin Distinguished Chair in Leukemia Research
Chief, CML & AML Sections
Deputy Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource, LLC, designates this live activity for a maximum of 22.0 *AMA PRA Category 1 Credits*™.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 22.0 Contact Hours.

This activity is supported by educational grants from Acerta Pharma – A member of the AstraZeneca Group, Celgene Corporation, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, Inc., NewLink Genetics, Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc.

PER® complies with the Physician Payments Sunshine Act as part of the Affordable Care Act. Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the Act.

For more information and to register, visit,
gotoper.com/go/HEM19NEWS1

PER® Physicians' Education Resource, LLC